MARTIN GUERRERO: Open Payments
NPI 1952591935 · EL PASO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$439,318 in 691 payments from 15 companies in 2025. Trend: 2023 $377,625 · 2024 $497,858 · 2025 $439,318
Speaker / faculty: $328,787Travel & lodging: $61,235Consulting: $18,803Food & beverage: $15,610Honoraria: $14,850Education: $33
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 216 | $168,014 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 137 | $87,168 |
| Otsuka America Pharmaceutical, Inc. | 139 | $77,218 |
| Neurocrine BioSciences, Inc. | 97 | $67,106 |
| E.R. Squibb & Sons, L.L.C. | 30 | $18,720 |
| Axsome Therapeutics, Inc. | 17 | $16,102 |
| ABBVIE INC. | 21 | $2,723 |
| Alkermes, Inc. | 5 | $481 |
| Lundbeck LLC | 9 | $456 |
| Teva Pharmaceuticals USA, Inc. | 5 | $376 |
Products named: FANAPT, CAPLYTA, REXULTI, INGREZZA, Auvelity, COBENFY, VRAYLAR, ARISTADA.
Industry payments across TX — which companies pay providers there.
